A meta-analysis of Watson for Oncology in clinical application

Abstract Using the method of meta-analysis to systematically evaluate the consistency of treatment schemes between Watson for Oncology (WFO) and Multidisciplinary Team (MDT), and to provide references for the practical application of artificial intelligence clinical decision-support system in cancer...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhou Jie, Zeng Zhiying, Li Li
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1438c25ad2a44b83901d82bc9683f6b9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1438c25ad2a44b83901d82bc9683f6b9
record_format	dspace
spelling	oai:doaj.org-article:1438c25ad2a44b83901d82bc9683f6b92021-12-02T13:19:30ZA meta-analysis of Watson for Oncology in clinical application10.1038/s41598-021-84973-52045-2322https://doaj.org/article/1438c25ad2a44b83901d82bc9683f6b92021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84973-5https://doaj.org/toc/2045-2322Abstract Using the method of meta-analysis to systematically evaluate the consistency of treatment schemes between Watson for Oncology (WFO) and Multidisciplinary Team (MDT), and to provide references for the practical application of artificial intelligence clinical decision-support system in cancer treatment. We systematically searched articles about the clinical applications of Watson for Oncology in the databases and conducted meta-analysis using RevMan 5.3 software. A total of 9 studies were identified, including 2463 patients. When the MDT is consistent with WFO at the ‘Recommended’ or the ‘For consideration’ level, the overall concordance rate is 81.52%. Among them, breast cancer was the highest and gastric cancer was the lowest. The concordance rate in stage I–III cancer is higher than that in stage IV, but the result of lung cancer is opposite (P < 0.05).Similar results were obtained when MDT was only consistent with WFO at the "recommended" level. Moreover, the consistency of estrogen and progesterone receptor negative breast cancer patients, colorectal cancer patients under 70 years old or ECOG 0, and small cell lung cancer patients is higher than that of estrogen and progesterone positive breast cancer patients, colorectal cancer patients over 70 years old or ECOG 1–2, and non-small cell lung cancer patients, with statistical significance (P < 0.05). Treatment recommendations made by WFO and MDT were highly concordant for cancer cases examined, but this system still needs further improvement. Owing to relatively small sample size of the included studies, more well-designed, and large sample size studies are still needed.Zhou JieZeng ZhiyingLi LiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Zhou Jie Zeng Zhiying Li Li A meta-analysis of Watson for Oncology in clinical application
description	Abstract Using the method of meta-analysis to systematically evaluate the consistency of treatment schemes between Watson for Oncology (WFO) and Multidisciplinary Team (MDT), and to provide references for the practical application of artificial intelligence clinical decision-support system in cancer treatment. We systematically searched articles about the clinical applications of Watson for Oncology in the databases and conducted meta-analysis using RevMan 5.3 software. A total of 9 studies were identified, including 2463 patients. When the MDT is consistent with WFO at the ‘Recommended’ or the ‘For consideration’ level, the overall concordance rate is 81.52%. Among them, breast cancer was the highest and gastric cancer was the lowest. The concordance rate in stage I–III cancer is higher than that in stage IV, but the result of lung cancer is opposite (P < 0.05).Similar results were obtained when MDT was only consistent with WFO at the "recommended" level. Moreover, the consistency of estrogen and progesterone receptor negative breast cancer patients, colorectal cancer patients under 70 years old or ECOG 0, and small cell lung cancer patients is higher than that of estrogen and progesterone positive breast cancer patients, colorectal cancer patients over 70 years old or ECOG 1–2, and non-small cell lung cancer patients, with statistical significance (P < 0.05). Treatment recommendations made by WFO and MDT were highly concordant for cancer cases examined, but this system still needs further improvement. Owing to relatively small sample size of the included studies, more well-designed, and large sample size studies are still needed.
format	article
author	Zhou Jie Zeng Zhiying Li Li
author_facet	Zhou Jie Zeng Zhiying Li Li
author_sort	Zhou Jie
title	A meta-analysis of Watson for Oncology in clinical application
title_short	A meta-analysis of Watson for Oncology in clinical application
title_full	A meta-analysis of Watson for Oncology in clinical application
title_fullStr	A meta-analysis of Watson for Oncology in clinical application
title_full_unstemmed	A meta-analysis of Watson for Oncology in clinical application
title_sort	meta-analysis of watson for oncology in clinical application
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1438c25ad2a44b83901d82bc9683f6b9
work_keys_str_mv	AT zhoujie ametaanalysisofwatsonforoncologyinclinicalapplication AT zengzhiying ametaanalysisofwatsonforoncologyinclinicalapplication AT lili ametaanalysisofwatsonforoncologyinclinicalapplication AT zhoujie metaanalysisofwatsonforoncologyinclinicalapplication AT zengzhiying metaanalysisofwatsonforoncologyinclinicalapplication AT lili metaanalysisofwatsonforoncologyinclinicalapplication
_version_	1718393255599538176

A meta-analysis of Watson for Oncology in clinical application

Ejemplares similares